Skip to content
HowShorted

2seventy bio, Inc. short interest in 2024

In 2024, 2seventy bio, Inc.'s disclosed short interest ran from 12.64% of shares outstanding on 12 Jan 2024 to 9.43% on 31 Dec 2024, a change of -3.21 percentage points. The year's high was 14.20% on 15 Jul 2024 and its low 9.07% on 13 Dec 2024, averaging 11.54% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 23.27 days on 15 Oct 2024. Full history: 2seventy bio, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2022 · 2023 · 2024 · 2025

Aggregate net short position time series for 2seventy bio, Inc. in 2024

2024 in figures

Start of year
12.64% (12 Jan 2024)
End of year
9.43% (31 Dec 2024)
Change
-3.21 pp
High
14.20% (15 Jul 2024)
Low
9.07% (13 Dec 2024)
Average
11.54%
Highest days to cover
23.27 (15 Oct 2024)
SEC filings marked
12

Every report in 2024

2seventy bio, Inc. short interest in 2024
SettlementShort interestDays to coverFilings since previous
12 Jan 202412.64%5.03
31 Jan 202412.57%2.91
15 Feb 202411.47%4.82results (8-K)
29 Feb 202410.90%8.07
15 Mar 202410.23%4.44results (8-K), 10-K filed
28 Mar 202413.26%3.28
15 Apr 202412.63%5.27
30 Apr 202413.56%8.13results (8-K)
15 May 202412.65%13.48results (8-K), 10-Q filed
31 May 202412.77%17.67
14 Jun 202411.97%9.61
28 Jun 202411.42%10.31
15 Jul 202414.20%12.02
31 Jul 202413.26%17.85results (8-K)
15 Aug 202412.42%18.88results (8-K), 10-Q filed
30 Aug 202411.56%19.31
13 Sep 20249.97%21.73
30 Sep 202410.33%12.60
15 Oct 202410.52%23.27
31 Oct 202410.51%23.09results (8-K)
15 Nov 20249.88%13.0510-Q filed, results (8-K)
29 Nov 20249.69%16.06
13 Dec 20249.07%20.51
31 Dec 20249.43%9.72

See also: 2seventy bio, Inc.'s full history · most shorted US stocks of 2024 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.